Geneva Advisors’s GenMark Diagnostics, Inc GNMK Stock Holding History

Geneva Advisors’s Portfolio GNMK Stock Details GNMK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-33,015	Closed	-$174K	–	758
2016 Q1	$174K	Sell	33,015 -1,512	-4%	-$8.42K	﹤0.01%	618
2015 Q4	$268K	Sell	34,527 -9,140	-21%	-$70.2K	0.01%	526
2015 Q3	$344K	Buy	43,667 +19,037	+77%	+$176K	0.01%	455
2015 Q2	$223K	Buy	24,630 +8,141	+49%	+$82.1K	﹤0.01%	586
2015 Q1	$214K	Buy	16,489 +2,843	+21%	+$37.2K	﹤0.01%	584
2014 Q4	$186K	Buy	+13,646	New	+$153K	﹤0.01%	609
2014 Q2	–	Sell	-32,354	Closed	-$322K	–	740
2014 Q1	$322K	Buy	32,354 +6,647	+26%	+$82.6K	0.01%	462
2013 Q4	$342K	Buy	25,707 +132	+0.5%	+$1.6K	0.01%	383
2013 Q3	$310K	Buy	25,575 +13,835	+118%	+$148K	0.01%	389
2013 Q2	$121K	Buy	+11,740	New	+$162K	﹤0.01%	402

Other funds holding GNMK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geneva Advisors's GNMK Position: Q2 2016 in Review

Geneva Advisors sold out of GenMark Diagnostics, Inc (GNMK) in Q2 2016, closing a stake of 33,015 shares — an estimated $174K sold.

Geneva Advisors first reported a position in GNMK in Q2 2013 and held it in 10 quarters. The position peaked at $344K in Q3 2015. 77 funds tracked by Wall St. Rank hold GNMK as of Q2 2016.

Geneva Advisors reported no remaining GenMark Diagnostics, Inc position as of Q2 2016 after selling out during the quarter.
Geneva Advisors sold 33,015 GenMark Diagnostics, Inc shares in Q2 2016, an estimated $174K.
Geneva Advisors first reported a position in GenMark Diagnostics, Inc in Q2 2013 and held it in 10 quarters.
Geneva Advisors's GenMark Diagnostics, Inc position peaked at $344K in Q3 2015.
77 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q2 2016.

Based on Geneva Advisors's 13F filing for Q2 2016, filed 8 Aug 2016.